NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.100
+0.056 (5.36%)
At close: May 12, 2025, 4:00 PM
1.120
+0.020 (1.82%)
After-hours: May 12, 2025, 7:27 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$600,588
Market Cap
26.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NRSN News
- 9 hours ago - Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - Benzinga
- 5 days ago - NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - PRNewsWire
- 18 days ago - NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - PRNewsWire
- 4 weeks ago - NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PRNewsWire
- 5 weeks ago - NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - PRNewsWire
- 5 weeks ago - NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PRNewsWire
- 2 months ago - PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Business Wire
- 4 months ago - NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - PRNewsWire